8-K: Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ovid Therapeutics announces business updates, Q4 and full year 2024 financial results, and key leadership appointments as it advances its clinical pipeline.

Summary

• Ovid Therapeutics reported its Q4 and full year 2024 financial results and provided business updates.
• The company appointed Stelios Papadopolous to its Board of Directors and added two industry veterans to its management team.
• Topline results from the Phase 1 study of OV329 are expected in Q3 2025.
• A first-in-human study for OV350, Ovid's first KCC2 direct activator, was initiated in Q1 2025.
• As of December 31, 2024, Ovid had $53.1 million in cash, cash equivalents, and marketable securities, expected to fund operations into the second half of 2026.
• Revenues from royalty agreements were $566,000 for the year ended December 31, 2024, compared to $392,000 for the same period in 2023.
• Research and development expenses were $36.8 million for the full year ended December 31, 2024, compared to $28.6 million for the same period in 2023.
• Ovid reported a net loss of $26.4 million, or $0.37 per share, for the year ended December 31, 2024, compared to a net loss of $52.3 million, or $0.73 per share, for the same period in 2023.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While there are positive developments in the pipeline and a reduced net loss, the pause of a Phase 2 study and the need for potential capital raising introduce uncertainty. The leadership changes are viewed as positive.

Positives

• Ovid has strengthened its leadership team with key appointments.
• The company's cash runway is expected to extend into the second half of 2026.
• Ovid is advancing a differentiated pipeline of potential first-in-class and best-in-class small molecule medicines.
• The net loss for 2024 decreased significantly compared to 2023.
• Revenues from royalty agreements increased from $392,000 in 2023 to $566,000 in 2024.

Negatives

• Ovid reported a net loss of $26.4 million for the year ended December 31, 2024.
• Ovid and Graviton Bioscience paused the initiation of the Phase 2 proof-of-concept study of OV888/ GV101 capsule.

Risks

• The company may need to delay or reduce research and development activities if it cannot raise capital or enter into partnerships.
• Clinical development and regulatory approval processes are inherently uncertain.
• Ovid's ability to achieve expected benefits of cost-savings efforts is not guaranteed.
• Ovid may not be able to realize the intended benefits of its business strategy.

Future Outlook

Ovid expects its cash runway to support operations and clinical development programs into the second half of 2026, during which time multiple pipeline and regulatory milestones are anticipated. The company will continue to explore partnerships and co-development opportunities for select programs and regions to accelerate development and offset costs.

Management Comments

• Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics, stated that the company is at an exciting inflection point and believes the team is the strongest it has been since the founding of the Company.
• Levin also noted that Stelios Papadopoulos' extensive industry expertise and strategic vision will be invaluable to Ovid through its next stage of growth.

Industry Context

Ovid's focus on developing small molecule medicines for brain conditions aligns with the growing interest in neurotherapeutics. The company's pipeline, including GABA-AT inhibitors and KCC2 activators, targets significant unmet needs in epilepsy, psychosis, and other neurological disorders. The pause in the OV888/GV101 study reflects the challenges and competitive landscape in the CCM (Cerebral Cavernous Malformation) space, where other companies have recently completed trials.

Comparison to Industry Standards

• Ovid's approach to GABA-AT inhibition with OV329, aiming for improved safety and tolerability compared to vigabatrin, mirrors the industry's trend toward developing next-generation therapies with enhanced profiles.
• The development of KCC2 direct activators like OV350 positions Ovid at the forefront of a novel therapeutic approach for neurological and psychiatric conditions, as KCC2 modulation is an emerging area of interest.
• The decision to pause the OV888/GV101 study after reviewing competitor data reflects a strategic approach to clinical development, similar to how other companies adapt their programs based on the evolving landscape.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the pipeline progress and reduced net loss, but concerned about the paused study and potential need for capital.
• Employees may be affected by potential delays or reductions in research and development activities if funding is not secured.
• Patients with neurological conditions may benefit from the development of new therapies targeting unmet needs.

Next Steps

• Ovid expects topline results from the Phase 1 study of OV329 in Q3 2025.
• The company anticipates initiating a Phase 2a patient study for OV329 in drug resistant epilepsies in Q1 2026.
• Ovid expects results from a first-in-human safety and exploratory biomarker study with OV350 in Q4 2025.
• The company anticipates initiating human studies with OV4071 in Q2 2026.

Key Dates